List view / Grid view

Cancer

 

article

Actualising the power of antibody-drug conjugates as cancer therapeutics

24 August 2022 | By ,

Antibody-drug conjugates (ADCs) are designed to be highly-targeted therapies with the potential to maximise the potency of a treatment while reducing unwanted side effects on healthy tissues. Some 20 years after the first ADC product approval, Dominik Schumacher and Jonas Helma-Smets of Tubulis GmbH discuss how improved and optimised technologies…